Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study
| Autor: | Akash Gupta, Vivek B. Kute, Himanshu V. Patel, Divyesh P. Engineer, Subho Banerjee, Pranjal R. Modi, Syed J. Rizvi, Vineet V. Mishra, Ansy H. Patel, Vijay Navadiya |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Blood transfusion medicine.medical_treatment India 030230 surgery Single Center law.invention Immunocompromised Host 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Risk Factors law Internal medicine medicine Humans Prospective Studies Prospective cohort study COVID-19 Serotherapy Kidney transplantation Transplantation business.industry Immunization Passive COVID-19 Middle Aged medicine.disease Kidney Transplantation Intensive care unit Transplant Recipients Treatment Outcome Feasibility Studies Female business Immunosuppressive Agents Kidney disease Cohort study |
| Zdroj: | Experimental and Clinical Transplantation. 19:304-309 |
| ISSN: | 2146-8427 1304-0855 |
| DOI: | 10.6002/ect.2020.0479 |
| Popis: | There are limited clinical data on feasibility and safety of convalescent plasma therapy in kidney transplant recipients with severe COVID-19. The present study was conducted to explore the feasibility of convalescent plasma treatment in 10 kidney transplant recipients with severe COVID-19.The prospective observational cohort study was conducted at the Institute of Kidney Disease and Research Centre, Ahmedabad, India. All patients were admitted to the intensive care unit and received antiviral therapy, glucocorticoids, and other supportive care. Two doses of 200 mL each of convalescent plasma with neutralization activity of1:640 were transfused into patients 24 hours apart following the World Health Organization blood transfusion protocol. The endpoints were the improvement of clinical symptoms and laboratory parameters within 1 day and 7 days after convalescent plasma transfusion.The patients showed resolution of clinical symptoms, and there was a significant decrease in inflammatory markers (P.05) within 7 days of convalescent plasma transfusion. Of the 10 patients, 9 patients had full recovery and 1 patient died.Convalescent plasma therapy is highly safe and clinically feasible and reduces mortality in kidney transplant recipients with severe COVID-19. Larger clinical registries and randomized clinical trials should be conducted to further explore the clinical outcomes associated with convalescent plasma use in kidney transplant recipients with severe COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|